AdvanCell raised a $315 million Series D to advance a lead-based radiopharmaceutical prostate cancer agent as well as to support U.S. manufacturing for Pluvicto challengers. The financing is positioned as a major step for scaling radioactive treatment capabilities and pushing lead candidates toward later-stage clinical development. The round stands out in radiopharma as competitors shift from discovery into industrialization—manufacturing capacity, supply chain reliability, and regulatory execution increasingly drive how quickly companies can run global trials. Elsewhere on the capital markets side, Deal logic also continues to concentrate, with a broader theme of AI-linked and clinical-stage differentiation drawing large rounds, even as tooling and non-AI segments show more uneven access to funding.